Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fisher & Paykel HealthcareASX:FPH +0.61%88 EV-to-EBITDA is 27.35 as of Jul. 22, 2026, which is 1% below its 10-year median of 27.65. GuruFocus rates ASX:FPH with a GF Score™ of 88/100 and a GF Value™ of A$36.64 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks worse than 78.24% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Fisher & Paykel Healthcare's enterprise value is A$18,826 Mil.
Fisher & Paykel Healthcare's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was A$688 Mil. Therefore, Fisher & Paykel Healthcare's EV-to-EBITDA for today is 27.35.
The historical rank and industry rank for Fisher & Paykel Healthcare's EV-to-EBITDA or its related term are showing as below:
ASX:FPH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 17.19 Med: 27.65 Max: 62.28
Current: 28.74
During the past 13 years, the highest EV-to-EBITDA of Fisher & Paykel Healthcare was 62.28. The lowest was 17.19. And the median was 27.65.
ASX:FPH's EV-to-EBITDA is ranked worse than 78.24% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 13.93
vs ASX:FPH: 28.74
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fisher & Paykel Healthcare's PE Ratio (TTM) for today is calculated as:
Fisher & Paykel Healthcare's share price for today is A$33.07.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fisher & Paykel Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.682.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:FPH vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's EV-to-EBITDA falls into.
Fisher & Paykel Healthcare's current Enterprise Value is A$18,826 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fisher & Paykel Healthcare's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was A$688 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare (ASX:FPH) has a EV-to-EBITDA of 27.35 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Fisher & Paykel Healthcare. This is near median its historical median of 27.65. Over the past decade, Fisher & Paykel Healthcare's EV-to-EBITDA has ranged from 17.19 to 62.28. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #399 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 78.2%.
Is Fisher & Paykel Healthcare's EV-to-EBITDA too high?
Fisher & Paykel Healthcare's current EV-to-EBITDA of 27.35 is near median its 10-year median of 27.65. Over the past 10 years, this metric has ranged from a low of 17.19 to a high of 62.28. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.93. Fisher & Paykel Healthcare's value of 27.35 is 96.3% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #399 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #399 out of 510 companies for EV-to-EBITDA. This places Fisher & Paykel Healthcare in the lower half of its industry. The industry median EV-to-EBITDA is 13.93. Fisher & Paykel Healthcare's value of 27.35 is 96.3% above this benchmark. Historically, Fisher & Paykel Healthcare's own EV-to-EBITDA has ranged from 17.19 to 62.28 over the past decade. While the company's 10-year median is 27.65 vs. the industry median of 13.93, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.93, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current EV-to-EBITDA of 27.35 is 96.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Fisher & Paykel Healthcare. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current EV-to-EBITDA is 27.35, which is near median its own 10-year median of 27.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Modestly Undervalued. The stock's GF Value™ is A$36.64, compared to a current price of A$33.07 — trading 9.7% below its estimated fair value. The current EV-to-EBITDA is 27.35, which is near median its 10-year median of 27.65 and 96.3% above the Medical Devices & Instruments industry median of 13.93. Fisher & Paykel Healthcare's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current EV-to-EBITDA is 27.35 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$33.07 is trading 9.7% below its estimated GF Value™ of A$36.64.
GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.
Key valuation signals for ASX:FPH:
EV-to-EBITDA: 27.35 (near median its 10-year median of 27.65)
GF Value™: A$36.64 vs. price of A$33.07 (9.7% below fair value)
Industry Position: 96.3% above the Medical Devices & Instruments median (#399 of 510)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
88GF Score
Get the complete analysis for ASX:FPH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
